-+ 0.00%
-+ 0.00%
-+ 0.00%

Citizens Maintains Market Outperform on Sutro Biopharma, Raises Price Target to $41

Benzinga·04/23/2026 14:34:10
Listen to the news
Citizens analyst Reni J. Benjamin maintains Sutro Biopharma (NASDAQ:STRO) with a Market Outperform and raises the price target from $35 to $41.